Peptide · Fact sheet

Lixisenatide

Also known as Adlyxin · Lyxumia · lixisenatide acetate · Soliqua 100/33 (with insulin glargine)

Lixisenatide has an FDA-approved adult diabetes use within Soliqua 100/33, the insulin glargine/lixisenatide combination. Standalone Adlyxin is discontinued. Lixisenatide is not approved for Parkinson disease or neuroprotection, and its Phase 2 Parkinson signal needs larger confirmation.

FDA approved for specific usesModerate human evidence

What is Lixisenatide?

Lixisenatide is a peptide GLP-1 receptor agonist developed for glucose control in type 2 diabetes.

Soliqua 100/33 contains both insulin glargine and lixisenatide; its approval and risks belong to that combination. Adlyxin was the standalone U.S. product.

Interest in Parkinson disease comes from possible brain and inflammatory effects of GLP-1 signaling, not from a diabetes approval.

Benefits & claims

The LIXIPARK trial reported less worsening on a motor score than placebo after one year.

That signal contrasts with a negative Phase 3 exenatide trial and makes replication, molecule differences, and study design especially important.

What the evidence supports

  • LIXIPARK found less average worsening on the primary motor score than placebo over the controlled period.
  • The study was not large enough to establish routine treatment, long-term disease modification, or broad class efficacy.
Research areas
  • Type 2 diabetes
  • Early Parkinson disease
  • Motor disability progression
  • GLP-1 neurobiology
  • Parkinson disease progression and neuroprotection

Dosage & frequency

Product-specific label information

Soliqua 100/33 is a labeled adult diabetes combination of insulin glargine and lixisenatide. Standalone Adlyxin is discontinued; its historical microgram regimen is separate.

Soliqua 100/33 combination

Adults with type 2 diabetes

Amount
15–60 insulin units of the fixed combination; maximum 60 units includes 20 mcg lixisenatide
Frequency
Once daily, within one hour before the first meal
Route studied or labeled
Subcutaneous

Starting amount depends on prior treatment; glucose-guided insulin titration and full-label safeguards apply. Not a standalone lixisenatide amount.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Soliqua 100/33 remains a separate labeled insulin glargine/lixisenatide combination for adult type 2 diabetes; its insulin-unit-based regimen cannot be taken from the historical Adlyxin amount.

Interactions & precautions

  • Insulin or insulin secretagogues increase hypoglycemia risk; delayed gastric emptying can affect oral medicines.

What is still unresolved

  • A historical label does not establish current availability or approval for neurologic disease.

Side effects & risks

  • Nausea and vomiting were frequent in the Parkinson trial and affected tolerability.
  • The Soliqua 100/33 label warns about pancreatitis, severe gastrointestinal reactions, kidney injury, hypoglycemia, and serious hypersensitivity. Its insulin component creates additional risks that cannot be assigned to lixisenatide alone.
  • The approved insulin combination, historical standalone product, and investigational Parkinson treatment are distinct formulations and evidence contexts.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Moderate human evidence

Diabetes evidence supports product-specific labeling, including the insulin glargine combination. The moderate rating reflects the Parkinson research emphasized here: a relatively small Phase 2 trial with a motor-score signal, substantial gastrointestinal adverse effects, and no proof of disease modification.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Appetite: reported experiences

No noticeable effect · personal report

Glucose remained high early in treatment

A Lyxumia forum participant described persistently high glucose and continued appetite after two weeks, while also taking metformin and following a lower-carbohydrate diet.

Reported use in this account

Product
Lyxumia
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Two weeks

Other exposures described: Metformin; A lower-carbohydrate diet

This July 2014 comment is an early, unverified observation during ongoing treatment changes. It does not establish longer-term effectiveness.

Read the original account

Approval status

FDA lists Soliqua 100/33 as a prescription product approved with diet and exercise for glycemic control in adults with type 2 diabetes. The standalone Adlyxin presentations are discontinued; this does not establish withdrawal of their approval. Neither product is approved for Parkinson disease.

Approved uses

  • Glycemic control in adults with type 2 diabetes through Soliqua 100/33 (insulin glargine/lixisenatide), alongside diet and exercise

Diabetes combination approved; standalone product discontinued

Soliqua 100/33 combines insulin glargine and lixisenatide for glycemic control in adults with type 2 diabetes. FDA lists this combination as prescription and standalone Adlyxin as discontinued. Neither diabetes approval establishes an approved Parkinson use.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether a larger confirmatory Parkinson trial will reproduce the motor signal
  • Whether the effect is symptomatic or disease modifying
  • Longer-term neurologic outcomes and tolerability
  • Why lixisenatide and exenatide trials produced different results

Summary

Lixisenatide offers a Parkinson research signal that needs confirmation. Soliqua 100/33 has an adult diabetes approval; discontinued standalone Adlyxin and experimental neurologic treatment remain separate contexts.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA Purple Book: Soliqua 100/33 product status

    FDA record identifying the insulin glargine/lixisenatide combination and its prescription marketing status.

  2. fdaFDA prescribing information: Soliqua 100/33

    Primary source for the practical reference information.

  3. fdaFDA Purple Book: Adlyxin product status

    FDA record showing approval details and discontinued marketing status.

  4. fdaFDA prescribing information: Adlyxin

    Former diabetes indication, warnings, adverse reactions, and clinical evidence.

  5. pubmedLIXIPARK randomized Phase 2 trial

    Controlled early-Parkinson study reporting a motor-score signal and gastrointestinal adverse effects.

  6. nihSoliqua 100/33 current prescribing information

    Current insulin glargine/lixisenatide combination labeling; not interchangeable with historical standalone Adlyxin.

How we assess sources · Suggest a correction